Abstracts tagged "ANCA associated vasculitis"

Abstract Number: 0435 • ACR Convergence 2021
Myeloperoxidase Activity in Individuals with Antineutrophil Cytoplasmic Antibodies (ANCA) Can Be Inhibited by RLS-0071
Parvathi Kumar¹, Pamela Hair¹, Ulrich Thienel¹, Kenji Cunnion¹, Neel Krishna² and Christos Gabriel³, ¹ReAlta Life Sciences Inc, Norfolk, VA, ²ReAlta Life Sciences Inc., Norfolk, VA, ³Children's Hospital of The King's Daughters, Norfolk
Background/Purpose: Anti-neutrophil cytoplasm antibodies (ANCA) are immunoglobulin G (IgG) autoantibodies directed against constituents of primary neutrophil granules (Davies, Moran et al. 1982). There is strong…
Abstract Number: 0419 • ACR Convergence 2021
Post-induction ANCA Titer Does Not Predict Mortality or Renal Outcomes: A Target Trial Emulation Study
Gregory McDermott¹, Xiaoqing Fu², Claire Cook³, John Stone⁴, Yuqing Zhang⁵ and Zachary Wallace⁶, ¹Brigham and Women's Hospital, Brookline, MA, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Harvard Medical School, Boston, MA, ⁶Massachusetts General Hospital, Newton, MA
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is associated with increased risk of end-stage renal disease (ESRD) and death. In most cases, circulating ANCA targeting…
Abstract Number: 0436 • ACR Convergence 2021
Ocular and Orbital Manifestations of Granulomatosis with Polyangiitis: A Systematic Review of Published Cases
Madeleine Yeakle¹, Allen Tsiyer¹, Daniel Bishev¹, Kayvon Moin¹, Victoria Garofalo¹, Allison Parrill¹, Alexander Hatsis², Tyler Wickas² and Prachi Anand³, ¹American University of the Caribbean School of Medicine, Cupecoy, Netherlands Antilles, ²Department of Ophthalmology, Nassau University Medical Center, East Meadow, NY, ³Department of Rheumatology, Nassau University Medical Center, East Meadow, NY
Background/Purpose: Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s Granulomatosis, is a systemic autoimmune condition caused by granulomatous inflammation of small and medium arteries, arterioles…
Abstract Number: 0420 • ACR Convergence 2021
Development and Validation of a Simulation Model for Maintenance Treatment in ANCA-Associated Vasculitis
Zachary Wallace¹, John Stone², Hyon K. Choi³ and Emily Hyle⁴, ¹Massachusetts General Hospital, Newton, MA, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Lexington, MA, ⁴Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA
Background/Purpose: ANCA-associated vasculitis (AAV) care has evolved over the last two decades with several approaches to remission maintenance. However, these approaches have trade-offs regarding the…
Abstract Number: 0437 • ACR Convergence 2021
Factors Associated with Reduced Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Treated with Rituximab
Victoria Furer¹, Tali Eviatar², Devy Zisman³, Hagit Peleg⁴, Daphna Paran⁵, David Levartovsky¹, Ilana Kaufman⁶, Michael Zisapel¹, Ofir Elalouf⁷, Roni Meidan¹, Adi Broyde⁸, Ari Polachek⁹, Jonathan Wollman⁷, Katya Meridor¹⁰, Hila Nochomovitz¹, Adi Silberman¹, Dana Rosenberg¹, Joy Feld¹¹, Amir Haddad¹², Tal Gazitt¹³, Muna Elias³, Nizar Hijaze¹⁴, Fadi Kharouf⁴, Gabi Shefer¹, Orly Sharon¹, Sara Pel¹, Sharon Nevo¹ and Ori Elkayam¹⁵, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Tel Aviv Sourasky Medical Center, Givataim, Israel, ³Carmel Medical Center, Haifa, Israel, ⁴Hadassah Medical Center, Jerusalem, Israel, ⁵Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel, ⁶Tel Aviv Sourasky Medical Center, Petach Tiqwa, Israel, ⁷Tel Aviv Medical Center, Herzliya, Israel, ⁸Tel Aviv Sourasky Medical Center, KIBBUTZ GIVAT HAIM I, Israel, ⁹Sourasky Medical Center, Petah-Tikva, Israel, ¹⁰Tel Aviv Sourasky Medical Center, Kfar Saba, Israel, ¹¹Carmel and Zvulun Medical Centre, Haifa, Israel, ¹²Carmel Medical Centre, Haifa, Israel, ¹³Carmel Hospital, Haifa, Israel, ¹⁴Carmel medical centre, Tamra, Israel, ¹⁵Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: Rituximab (RTX) has been associated with impaired humoral response to vaccination. This study aim was to identify the predictors for a lack of humoral…
Abstract Number: 0421 • ACR Convergence 2021
Negative vs. Positive Antineutrophil Cytoplasmic Antibody Granulomatosis with Polyangiitis, a Case-control Study
Marta Casal Moura, Samuel D. Falde, Ulrich Specks and Misbah Baqir, Mayo Clinic, Rochester, MN
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA) negative granulomatosis with polyangiitis (GPA) is a challenging diagnosis. There is paucity of literature regarding the clinical course of ANCA-negative…
Abstract Number: 0525 • ACR Convergence 2021
STEAP3, FZD2 and EGFLAM Are Novel Genetic Risk Loci for Granulomatosis with Polyangitis: A Genome Wide Association Study from UK Biobank
Mehmet Hocaoglu¹, Jamal Mikdashi², Yi-Ju Chen², James Perry² and Charles Hong², ¹University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Granulomatosis with Polyangitis (GPA) is a systemic ANCA associated small vessel vasculitis. Prior genetic studies demonstrated a strong association of HLA Class II region…
Abstract Number: 0422 • ACR Convergence 2021
Cancer in Patients with ANCA-associated Vasculitis: Which Came First, the Chicken or the Egg?
Elif Ediboglu¹, Riza Can Kardas², Ertugrul Cagri bolek³, Resit Yildirim⁴, DenizCan Guven⁵, Saadettin Kilickap⁵, Omer Dizdar⁵, Melek Yalcin Mutlu⁶, Ozan Cemal Icacan⁷, Gizem Ayan⁸, Emre Bilgin⁸, Nazife Sule Yasar Bilge⁹, Levent Kilic⁸, Timucin Kasifoglu⁴, Cemal Bes¹⁰, Servet Akar¹¹ and Omer Karadag¹², ¹Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ²Hacettepe University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, ³Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham, MD, ⁴Eskisehir Osmangazi University, Department of Internal Medicine, Division of Rheumatology, Eskisehir, Turkey, ⁵Hacettepe University Medical Faculty, Department of Medical Oncology, Ankara, Turkey, ⁶University of Health Sciences, Istanbul, ⁷University of Health Sciences, Istanbul, Turkey, ⁸Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁹Eskisehir Osmangazi University Medical Faculty, Eskisehir, Turkey, ¹⁰Saglik Bilimleri University, Basaksehir Cam and Sakura State Hospital – Istanbul, Turkey, Istanbul, Turkey, ¹¹Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ¹²Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey
Background/Purpose: Many studies linking vasculitis to the development of malignancy based on chronic inflammation, cytotoxicity, emergence of vasculitis as a paraneoplastic disease. Even previous studies…
Abstract Number: 0533 • ACR Convergence 2021
Identification of a Novel Susceptibility Locus for Small Vessel Vasculitis with Autoantibodies Against Myeloperoxidase
Johanna Dahlqvist¹, Diana Ekman², Bengt Sennblad², Sergey Kozyrev³, Jessika Nordin², Åsa Karlsson³, Jennifer Meadows³, Erik Hellbacher¹, Solbritt Rantapaa-Dahlqvist⁴, Ewa Berglin⁵, Bernd Stegmayr⁵, Bo Baslund⁶, Øyvind Palm⁷, Hilde Haukeland⁷, Iva Gunnarsson⁸, Annette Bruchfeld⁸, Mårten Segelmark⁹, Sophie Ohlsson⁹, Aladdin Mohammad⁹, Anna Svärd¹⁰, Rille Pullerits¹¹, Hans Herlitz¹¹, Annika Söderbergh¹², Gerli Rosengren Pielberg³, Fabiana Farias³, Lina Hultin Rosenberg³, Matteo Bianchi³, Eva Muren³, Roald Omdal¹³, Roland Jonsson¹⁴, Maija-Leena Eloranta³, Lars Ronnblom³, Peter Söderkvist¹⁵, Ann Knight¹⁶, Per Eriksson¹⁵ and Kerstin Lindblad-Toh¹⁷, ¹Uppsala University and University Hospital, Uppsala, Sweden, ²Science for Life Laboratory, Uppsala University, Uppsala, Sweden, ³Uppsala University, Uppsala, Sweden, ⁴Ume University, Umea, Sweden, ⁵Umeå University and University Hospital, Umeå, Sweden, ⁶University of Copenhagen, Copenhagen, Denmark, ⁷Oslo University, Oslo, Norway, ⁸Karolinska Institute, Stockholm, Sweden, ⁹Lund University, Lund, Sweden, ¹⁰Uppsala University, Falun, Sweden, ¹¹Gothenburg University and Sahlgrenska Hospital, Gothenburg, Sweden, ¹²Dept. of Rheumatology, Örebro University Hospital, Örebro, Sweden, ¹³Stavanger University Hospital and University of Bergen, Stavanger, Norway, ¹⁴University of Bergen, Bergen, Norway, ¹⁵Linköping University, Linköping, Sweden, ¹⁶Rheumatology, Institute of Medical Sciences, Uppsala University, Uppsala, Sweden, ¹⁷Broad Institute of MIT and Harvard; and Uppsala University, Boston, MA
Background/Purpose: ANCA-associated vasculitides (AAV) are rare but aggressive autoimmune disorders. The pathogenesis of the disorders is complex and still poorly understood; only a few genetic…
Abstract Number: 0423 • ACR Convergence 2021
Urine and Plasma Complement Ba Levels During Flares of Nephritis in Patients with ANCA-Associated Vasculitis
Salem Almaani¹, Huijuan Song², Meshora Sthanithra², Christopher Toy², Anna Levesque², Lynn Fussner³, Alexa Meara³, Haikady Nagaraja², David Cuthbertson⁴, Nader Khalidi⁵, CURRY LEE MD KOENING⁶, Carol Langford⁷, Carol McAlear⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Antoine Sreih¹², Kenneth Warrington¹³, Paul Monach¹⁴, Peter Merkel⁸, Brad Rovin³ and Dan Birmingham², ¹Ohio State University Medical Center, Columbus, OH, ²Ohio State university, Columbus, OH, ³Ohio State University Wexner Medical Center, Columbus, OH, ⁴University of South Florida, Tampa, FL, ⁵McMaster University, Hamilton, ON, Canada, ⁶LIMITED TO OFFICIAL UNIVERSITY DUTIES ONLY, Salt Lake City, UT, ⁷Cleveland Clinic, Moreland Hills, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹University of Colorado, Denver, CO, ¹⁰Mount Sinai Hospital, Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Univeristy of Pennsylvania, Philadelphia, PA, ¹³Mayo Clinic, Rochester, Minnesota, ¹⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: The alternative complement pathway has been implicated in the pathogenesis of ANCA-associated vasculitis (AAV), however it is not clear whether activation of complement occurs…
Abstract Number: 0952 • ACR Convergence 2021
Outcomes of COVID-19 Infection in Patients with Primary Systemic Vasculitis and Polymyalgia Rheumatica: Results from the COVID-19 Global Rheumatology Alliance Physician Registry
Sebastian Sattui¹, Richard Conway², Michael Putman³, Andrea Seet⁴, Kaley Beins⁵, Catherine Hill⁶, David Liew⁷, Sarah Mackie⁸, Puja Mehta⁹, Lorna Neill¹⁰, Gimena Gomez¹¹, Maria Salinas¹², Federico Maldonado¹³, Henrique Moriz¹⁴, Samia Studart¹⁵, NAFICE ARAUJO¹⁶, Ann Knight¹⁷, Davide Rozza¹⁸, Luca Quartuccio¹⁹, Maxime Samson²⁰, Stephane Bally²¹, Alexandre Maria²², Pascal Chazerain²³, Rebecca Hasseli²⁴, Ulf Müller-Ladner²⁵, Bimba Franziska Hoyer²⁶, Reinhard Voll²⁷, Rita Pinheiro Torres²⁸, Mariana Luis²⁹, Sandra Lúcia Ribeiro³⁰, Samar Al Emadi³¹, Jeffrey Sparks³², Tiffany Hsu³³, Kristin D'Silva³⁴, Naomi Patel³⁴, Leanna Wise³⁵, Emily Gilbert³⁶, Maria Valenzuela-Almada³⁷, Ali Duarte-Garcia³⁸, Manuel Ugarte-Gil³⁹, Emily Sirotich⁴⁰, Jean Liew⁴¹, Jonathan Hausmann⁴², Paul Sufka⁴³, Suleman Bhana⁴⁴, Rebecca Grainger⁴⁵, Wendy Costello⁴⁶, Lindsay Jacobsohn⁴⁷, Zara Izadi⁴, Anja Strangfeld⁴⁸, Elsa Frazão Mateus⁴⁹, Kimme Hyrich⁵⁰, Laure Gossec⁵¹, Loreto Carmona⁵², Saskia Lawson-Tovey⁵⁰, Lianne Kearsley-Fleet⁵³, Martin Schaefer⁵⁴, Milena Gianfrancesco⁴, Pedro Machado⁵⁵, Zachary Wallace³⁴, Jinoos Yazdany⁴ and Philip Robinson⁵⁶, ¹Hospital for Special Surgery, New York, NY, ²St. James's University Hospital, Dublin, Ireland, ³Medical College of Wisconsin, Brookfield, WI, ⁴University of California San Francisco, San Francisco, CA, ⁵Vasculitis Foundation, Kansas City, MO, ⁶Queen Elizabeth Hospital, Woodville, Australia, ⁷Austin Health, Heidelberg, Australia, ⁸School of Medicine, University of Leeds, Leeds, United Kingdom, ⁹University College London, London, United Kingdom, ¹⁰PMR GCA Scotland, Perth, United Kingdom, ¹¹Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, ¹²Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ¹³Sanatorio Güemes, Buenos Aires, Argentina, ¹⁴Hospital das Clinicas, Universidade Federal de Pernambuco, Pernambuco, Brazil, ¹⁵HOSPITAL GERAL DE FORTALEZA, Fortaleza, Brazil, ¹⁶Instituto de ASsistencia Medica ao Servidor Publico Estadual de São Paulo, São Paulo, Brazil, ¹⁷Rheumatology, Institute of Medical Sciences, Uppsala University, Uppsala, Sweden, ¹⁸Epidemiology Research Unit, Italian Society of Rheumatology, Rome, Italy, ¹⁹Clinical Rheumatology, Department of Medicine, University of Udine, Udine, Italy, ²⁰CHU Dijon Bourgogne, Hpital Franois Mitterrand, Dijon, Dijon, France, ²¹Nephrology and Dialysis Service, Metropole Savoie Hospital Center, Chambery, France, ²²Department of Internal Medicine and Multiorganic Diseases, Saint-Eloi University Hospital of Montpellier, Montpellier, France, ²³Department of Rheumatology and Internal Medicine, Diaconesses Croix Saint Simon Hospital, Paris, France, ²⁴Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Bad Nauheim, Germany., Bad Nauheim, Germany, ²⁵JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany, ²⁶Universittsklinikum Schleswig-Holstein, Kiel, Germany, ²⁷Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, ²⁸Rheumatology Service, Egas Moniz Hospital, Lisboa Occidental Hospital Centre, Lisbon, Portugal, ²⁹Department of Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portuga, Coimbra, Portugal, ³⁰Universidade Federal do Amazonas, Amazonas, Brazil, ³¹Hamad medical corporation, Doha, Qatar, ³²Brigham and Women's Hospital, Boston, MA, ³³Brigham and Women's Hospital, Jamaica Plain, MA, ³⁴Massachusetts General Hospital, Boston, MA, ³⁵LAC+USC/Keck Medicine of USC, Pasadena, CA, ³⁶Mayo Clinic, Jacksonville, FL, ³⁷Division of Rheumatology, Mayo Clinic, Rochester, MN, ³⁸Mayo Clinic, Rochester, MN, ³⁹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ⁴⁰McMaster University, Hamilton, ON, Canada, ⁴¹Boston University, Boston, MA, ⁴²Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁴³HealthPartners, Eagan, MN, ⁴⁴Crystal Run Health, Montvale, NJ, ⁴⁵University of Otago, Wellington, New Zealand, ⁴⁶Irish Children's Arthritis Network, Bansha, Ireland, ⁴⁷University of California San Francisco, Antioch, CA, ⁴⁸Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁴⁹Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, ⁵⁰University of Manchester, Manchester, United Kingdom, ⁵¹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ⁵²Instituto de Salud Musculoesqueltica (InMusc), Madrid, Spain, ⁵³Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁵⁴German Rheumatism Research Center, Berlin, Germany, ⁵⁵Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁵⁶University of Queensland School of Clinical Medicine, Brisbane, Queensland, Australia, Herston, Australia
Background/Purpose: Patients with primary systemic vasculitis (PSV) and polymyalgia rheumatica (PMR) may be at high risk for poor COVID-19 outcomes due to the treatments used,…
Abstract Number: 0425 • ACR Convergence 2021
Diagnostic Accuracy of Muscle MRI for Muscular Vasculitis in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis: A Pilot Study
Ryuta Inaba, Daisuke Waki, Keisuke Nishimura, Tomohiro Yoshida, Kaoru Mizukawa, Shintaro Yamamoto, Osamu Iri, Kohei Yo and Hiroyuki Murabe, Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, Kurashiki, Japan
Background/Purpose: Histopathologic confirmation is the golden standard for diagnosis of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), but sometimes can be difficult because of its invasion (e.g.…
Abstract Number: 0953 • ACR Convergence 2021
An International Delphi Exercise to Identify Items of Importance for Measuring Response to Treatment for ANCA-associated Vasculitis
Kaitlin Quinn¹, Sara Monti², Georgia Lanier³, Maria Bjork Viðarsdóttir⁴, Robin Christensen⁵, David R.W. Jayne⁶, Carol Langford⁷, Alfred Mahr⁸, Christian Pagnoux⁹, Gunnar Tomasson¹⁰ and Peter Merkel¹¹, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ²University of Pavia, Pavia, Italy, ³n/a, Sherborn, MA, ⁴n/a, Reykjavik, Iceland, ⁵Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen & Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Copenhagen, Denmark, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷Cleveland Clinic, Moreland Hills, OH, ⁸Kantonsspital St. Gallen, St.Gallen, Switzerland, ⁹Mount Sinai Hospital, Toronto, ON, Canada, ¹⁰University of Iceland, Reykjavik, Iceland, ¹¹University of Pennsylvania, Philadelphia, PA
Background/Purpose: ANCA-associated vasculitis (AAV) is characterized by fluctuating levels of disease activity. Randomized controlled trials (RCTs) in AAV have used multiple instruments to define active…
Abstract Number: 0426 • ACR Convergence 2021
Ocular Manifestations of ANCA-Associated Vasculitis
Mats Junek¹, Stephanie Garner¹, Lily Zhao¹, David Cuthbertson², Christian Pagnoux³, CURRY LEE MD KOENING⁴, Carol Langford⁵, Carol McAlear⁶, Paul Monach⁷, Larry Moreland⁸, Philip Seo⁹, Ulrich Specks¹⁰, Antoine Sreih¹¹, Kenneth Warrington¹⁰, Peter Merkel⁶ and Nader Khalidi¹, ¹McMaster University, Hamilton, ON, Canada, ²University of South Florida, Tampa, FL, ³Mount Sinai Hospital, Toronto, ON, Canada, ⁴LIMITED TO OFFICIAL UNIVERSITY DUTIES ONLY, Salt Lake City, UT, ⁵Cleveland Clinic, Moreland Hills, OH, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Brigham and Women's Hospital, Boston, MA, ⁸University of Colorado, Denver, CO, ⁹Johns Hopkins University, Baltimore, MD, ¹⁰Mayo Clinic, Rochester, MN, ¹¹Univeristy of Pennsylvania, Philadelphia, PA
Background/Purpose: ANCA-associated vasculitides (AAV) are multisystem diseases that can have multiple ophthalmic manifestations. Although there are some data on ocular disease in granulomatosis with polyangiitis…
Abstract Number: 0954 • ACR Convergence 2021
The Association of Rituximab- vs. Cyclophosphamide-Based Remission Induction Strategies with Risk of End-Stage Renal Disease and Death in ANCA-Associated Vasculitis
Zachary Wallace¹, Xiaoqing Fu², Claire Cook³, Yuqing Zhang⁴, John Stone⁵ and Hyon K. Choi⁶, ¹Massachusetts General Hospital, Newton, MA, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Harvard Medical School, Boston, MA, ⁵Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁶Massachusetts General Hospital, Lexington, MA
Background/Purpose: The RAVE trial established the non-inferiority of rituximab (RTX) vs cyclophosphamide (CYC) for remission induction of ANCA-Associated Vasculitis (AAV). Patients in RAVE were followed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].